… A search of ClinicalTrials.gov showed that several randomised trials comparing EGFR tyrosine
kinase inhibitors are ongoing, including: a phase 2 trial comparing erlotinib and gefitinib (…

… To our knowledge, this is the first large randomized clinical trial of an MET-targeted inhibitor
to be reported in NSCLC. We evaluated erlotinib plus the specific MET inhibitor tivantinib …

… Several prospective clinical trials of gefitinib or erlotinib for treatment of non–small cell lung
… review and meta-analysis of individual patient data from 16 randomized controlled trials. …

… The aim of this study was to evaluate the efficacy of erlotinib … analysis of randomized controlled
trials that compared erlotinib-… EGFR pathway, such as gefitinib and erlotinib. To date, the …

… III trial that randomly assigned 731 patients to erlotinib 150 mg … Gefitinib has now been
compared with docetaxel in the … randomized phase II and two randomized phase III trials. These …

… use of erlotinib or gefitinib in early-… study confirms the antitumor activity of erlotinib as first-line
therapy in patients with NSCLC who may be poor candidates for chemotherapy. This study …

… study showed that sensitivity to erlotinib and gefitinib differed among several EGFR mutations
at exon 19 [35]. Moreover, gefitinib and erlotinib … following clinical trials compared gefitinib …

… Our purpose of this study is to investigate how afatinib is used in real-world practice, and
whether it leads to different clinical outcomes compared with gefitinib or erlotinib. …

… define the course of patients following TKI discontinuation, we systematically evaluated
patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib. …

… randomized controlled trial to directly compare lower dose erlotinib with standard dose gefitinib
… Therefore, in Stage IV EGFR mutated NSCLC, this study showed that erlotinib 100 mg/d …